Micro RNA

MicroRNAs establish an as of late found class of non-coding RNAs that assume key jobs in the guideline of quality articulation. As per the International Agency for Research on Cancer (IARC), a specific organization of the WHO, about 12.7 million new malignant growth cases were accounted for in 2008 and the number arrived at 14.1 million out of 2012. MicroRNAs are utilized as a biomarker for malignant growth determination and treatment.

A portion of the significant organizations working in the worldwide microRNA advertise are Affymetrix Inc., Alnylam Pharmaceuticals Inc., Santaris Pharma A/S, Exelon A/S, AstraZeneca Pharmaceuticals LP, Biogenic Idec Inc., Eli Lilly and Co., Pfizer Inc., CBC Comprehensive Biomarker Centre GmbH, F. Hoffman-La Roche, GlaxoSmithKline, Merck and Co. Inc., Novartis AG and Sigma-Aldrich. GlaxoSmithKline (GSK) has built up coordinated effort with Regales Therapeutics to create and popularize therapeutics focusing on microRNA-122 for hepatitis C infection (HCV) disease.


    Related Conference of Micro RNA

    November 30-30, 2020

    Genetics and Molecular biology

    Paris, France
    December 07-08, 2020

    2nd World Congress on Cell and Structural Biology

    Sydney, Australia
    December 09-09, 2020

    International Conference on Toxicogenomics

    Bali, Indonesia

    Micro RNA Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in